N-Hydroxynortropinon | 54807-24-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: N-Hydroxynortropinon
• 英文别名: 8-hydroxy-nortropan-3-one；8-Hydroxy-8-azabicyclo[3.2.1]octan-3-one
• CAS: 54807-24-8
• 化学式: C₇H₁₁NO₂
• mdl: MFCD24390356
• 分子量: 141.17
• InChiKey: IHBAYRYWEQNTGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Methods of producing an HIV maturation inhibitor
  申请人：ViiV HEALTHCARE UK (NO.4) LIMITED

  公开号：US10221208B2

  公开（公告）日：2019-03-05

  A method for producing HIV maturation inhibitor compound is set forth using betulin as starting material, and utilizing Lossen rearrangement techniques.

  提出了一种利用白桦脂生产艾滋病病毒成熟抑制剂化合物的方法 作为起始原料，利用洛森重排技术生产艾滋病毒成熟抑制剂化合物的方法。
• METHODS OF PRODUCING AN HIV MATURATION INHIBITOR
  申请人：VIIV Healthcare UK(No.4) Limited

  公开号：EP3283467A1

  公开（公告）日：2018-02-21
• CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY
  申请人：VIIV HEALTHCARE UK (NO.4) LIMITED

  公开号：US20180094019A1

  公开（公告）日：2018-04-05

  The present invention relates to crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity. More specifically, the present invention relates to the H-4, T1F-1, and T1F-2 crystalline forms. The present invention also relates to pharmaceutical compositions comprising these crystalline forms, as well as to methods of using these crystalline forms for the treatment of the HIV virus, and methods for obtaining these crystalline forms.
• [EN] CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY<br/>[FR] FORMES CRISTALLINES DE SELS DE CHLORHYDRATE TRITERPÉNOÏDES MODIFIÉS PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016168462A1

  公开（公告）日：2016-10-20

  The present invention relates to crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity. More specifically, the present invention relates to the H-4, TlF-1, and TlF-2 crystalline forms. The present invention also relates to pharmaceutical compositions comprising these crystalline forms, as well as to methods of using these crystalline forms for the treatment of the HIV virus, and methods for obtaining these crystalline forms.
• [EN] METHODS OF PRODUCING AN HIV MATURATION INHIBITOR<br/>[FR] MÉTHODES DE PRODUCTION D'UN INHIBITEUR DE LA MATURATION DU VIH
  申请人：VIIV HEALTHCARE (NO 4) LTD

  公开号：WO2016168447A1

  公开（公告）日：2016-10-20

  A method for producing HIV maturation inhibitor compound is set forth using betulin Chemical Structure (I) as starting material, and utilizing Lossen rearrangement techniques.